Paul Mensah leads the Bioprocess R&D and Drug Substance Supply group in Pfizer’s BioTherapeutics Pharmaceutical Sciences organization, with sites in Andover, MA, Chapel Hill, NC, Pearl River, NY, and St. Louis, MO. The group is responsible for developing innovative and compliant manufacturing processes for biotherapeutics, including gene therapy and vaccines. Paul has a global scope of responsibilities, overseeing and providing strategic direction to the scientific and operational implementation plans for all aspects of bioprocess technologies and activities to support Pfizer’s growing portfolio.
Paul joined Pfizer in 1999 and prior to his current role, Paul led the Culture Process Development group in Bioprocess R&D, which is responsible for the development, characterization, transfer, and scale-up of cell culture and fermentation processes from the regulatory toxicology stage through to licensure. In the early part of his career, Paul held roles in the Purification Process Development group and has led teams for several biotherapeutics, helping to steer them through clinical development, from Phase 1 through Phase 3. He also served as a Research Project Leader for an asset in the Rare Disease Research Unit.
Paul is trained as a Chemical Engineer with degrees from Cornell University (B.S.) and the University of Virginia (Ph.D.). He is a member of the American Institute of Chemical Engineers and the Society of Biological Engineers. Paul serves on the advisory board of the Chemical Engineering Department at the University of Virginia and is a member of the External Advisory Committee for the CHO-g2p Advanced Biomanufacturing project, an NSF-funded project involving Clemson University, University of Delaware, Tulane University and Delaware State University.